LSA
TERN

Leonteq Securities AG’s Terns Pharmaceuticals TERN Stock Holding History

Leonteq Securities AG’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$4.04K – 1483
2025
Q4 		$4.04K Buy
+100
New +$2.31K ﹤0.01% 1272
2024
Q4 		– Sell
-16,000
Closed -$133K – 1330
2024
Q3 		$133K Buy
+16,000
New +$132K 0.01% 570

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Leonteq Securities AG's TERN Position: Q1 2026 in Review

Leonteq Securities AG sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 100 shares — an estimated $4.04K sold.

Leonteq Securities AG first reported a position in TERN in Q3 2024 and held it in 2 quarters. The position peaked at $133K in Q3 2024. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Leonteq Securities AG reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Leonteq Securities AG sold 100 Terns Pharmaceuticals shares in Q1 2026, an estimated $4.04K.
  • Leonteq Securities AG first reported a position in Terns Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Leonteq Securities AG's Terns Pharmaceuticals position peaked at $133K in Q3 2024.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Leonteq Securities AG's 13F filing for Q1 2026, filed 27 Apr 2026.